- Trial represents a key component of onvansertib's KRAS-targeted clinical programs and is designed to leverage the synergy of onvansertib when combined with irinotecan/5-FU
- The first patient was dosed at the Mayo Clinic Cancer Center, Jacksonville; study to enroll 40 patients at six sites in the U.S.
PR Newswire
SAN DIEGO, June 8, 2021